New cholesterol jabs offer hope for patients struggling with traditional statins

For many, the struggle against high cholesterol means a lifelong commitment to daily tablets. However, for those who find statins insufficient or unbearable, a modern medical breakthrough is offering a fresh start.

Dr Naveen Bhamri, a leading cardiologist with 27 years of experience, has highlighted that while injections are a "game changer," they are specifically tailored for those in greatest need.

Dr Bhamri explains that these treatments are not for everyone. He noted: “Injections are available, but they are for those who cannot tolerate statins, who do not reach their target LDL levels despite statins, those who have high-risk heart disease and are experiencing recurrent heart attacks, or those with familial hypercholesterolemia.

"Within these four categories, we can use injectable therapy.” Essentially, for patients with genetic conditions or those facing repeat heart scares, this is a vital lifeline.

The treatment involves targeting the PCSK9 protein to help the liver flush out "bad" cholesterol. Patients have two main routes: a bi-weekly subcutaneous jab or the long-acting Inclisiran.

Regarding the latter, Dr Bhamri said: "This also inhibits PCSK9, but the mechanism is slightly different. It is long-acting, and two or three injections need to be taken per year."

For the right person, this is more than just a matter of convenience; it is a powerful tool for survival. As Dr Bhamri concludes, "It is safe, effective, and significantly reduces the risk of heart attacks."

It is a reassuring step forward for heart health, moving beyond the pharmacy counter to offer more personalised, long-term protection.

This content is meant for informational purposes only and should not replace professional medical advice.